Competition and Drug Pricing in the PBS: An Economic Interpretation

[thumbnail of Full Paper]
Preview
15916.pdf (58kB) | Preview

Sheehan, Peter and Sweeny, Kim (2002) Competition and Drug Pricing in the PBS: An Economic Interpretation. Working Paper. Victoria University, Melbourne, Australia.

Abstract

The paper will describe and attempt to assess some of the evidence in relation to six hypotheses. It is very preliminary. In its subsequent development it will attempt to pull together evidence from international sources and other Australian studies, from our case studies and from our analyses of various data sources, to assess these hypotheses. The six hypotheses are as follows. 1. Increasing Role of Benefit Paid Pharmaceuticals. 2. Highly Regulated Prices, with Administered Competition. 3. Extensive Non-Price Competition between Suppliers. 4. Low and Short-Lived Returns to Innovation. 5. Relatively High Price, Low Volume Approach to Generics. 6. Duopoly Situation for Many Post-Patent Drugs.

Dimensions Badge

Altmetric Badge

Additional Information

Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper

Item type Monograph (Working Paper)
URI https://vuir.vu.edu.au/id/eprint/15916
DOI No. 12
Subjects Historical > FOR Classification > 1402 Applied Economics
Historical > Faculty/School/Research Centre/Department > Centre for Strategic Economic Studies (CSES)
Keywords Pharmaceuticals Benefit Scheme, PBS, Australian health system
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login